| Literature DB >> 26658659 |
Rosa M Barsova1, Dmitrijs Lvovs2, Boris V Titov1,3, Natalia A Matveeva1,3, Roman M Shakhnovich4, Tatiana S Sukhinina4, Nino G Kukava4, Mikhail Ya Ruda4, Irina M Karamova5, Timur R Nasibullin6, Olga E Mustafina6, German J Osmak3, Ekaterina Yu Tsareva1,3, Olga G Kulakova1,3, Alexander V Favorov2,7, Olga O Favorova1,3.
Abstract
BACKGROUND: In spite of progress in cardiovascular genetics, data on genetic background of myocardial infarction are still limited and contradictory. This applies as well to the genes involved in inflammation and coagulation processes, which play a crucial role in the disease etiopathogenesis. METHODS ANDEntities:
Mesh:
Substances:
Year: 2015 PMID: 26658659 PMCID: PMC4675542 DOI: 10.1371/journal.pone.0144190
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
SNPs positively associated with MI in discovery (325 MI patients and 185 controls from Moscow) and in independent replication group (220 MI patients and 197 controls from Bashkortostan, men only).
| Gene, SNP | Carriage of risk genotypes (alleles) | Discovery group (Moscow) | Independent replication group (Bashkortostan, men only) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Frequency (case/control) | Fisher | Permutation | OR (95% CI) | Frequency (case/control) | Fisher | Permutation | OR (95% CI) | ||
|
| TT | 0.47/0.32 | 0.00098 | 0.0082 | 1.84 (1.26–2.68) | 0.46/0.32 | 0.0025 | 0.013 | 1.79 (1.20–2.67) |
|
| TT+CT (T) | 0.52/0.38 | 0.0012 | 0.0086 | 1.80 (1.24–2.61) | 0.51/0.37 | 0.0021 | 0.011 | 1.80 (1.21–2.66) |
|
| TT | 0.12/0.04 | 0.0030 | 0.020 | 2.93 (1.34–6.41) | 0.15/0.04 | 0.00011 | 0.00026 | 4.17 (1.87–9.26) |
* 100 permuted APSampler runs.
Allelic combinations associated with MI according to APSampler analysis in discovery group (325 MI patients and 185 controls from Moscow) and in independent replication group (220 MI patients and 197 controls from Bashkortostan, men only).
| Carriage of allele combinations | Discovery group (Moscow) | Independent replication group (Bashkortostan, men only) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Carriers, frequency (case/control) |
| OR (95% CI) | SF (95% CI) |
| Carriers, frequency (case/control) |
| OR (95% CI) | SF (95% CI) |
| |
|
| 0.49/0.66 | 0.000036 (0.00048) | 0.46 (0.31–0.67) | 0.39 (0.086–1.77) | 0.26 | 0.45/0.65 | 0.000031 (0.000055) | 0.44 (0.29–0.65) | 0.66 (0.13–3.41) | 0.67 |
|
| 0.48/0.30 | 0.000057 (0.00068) | 2.15 (1.46–3.15) | 2.22 (0.78–6.33) | 0.18 | 0.45/0.30 | 0.00077 (0.004) | 1.94 (1.30–2.92) | 1.35 (0.44–4.15) | 0.77 |
|
| 0.14/0.05 | 0.0015 (0.0095) | 2.97 (1.41–6.23) | 5.18 (1.46–18.4) | 0.018 | 0.16/0.07 | 0.0021 (0.011) | 2.67 (1.37–5.22) | 7.27 (1.72–30.8) | 0.0012 |
* pf−Fisher p value; p perm−permutation p value (100 permuted APSampler runs).
** p FLINT−p value according to exact Fisher-like interaction numeric test (FLINT).
Fig 1ROC curves demonstrate usefulness of the additive composite model built from all identified genetic markers.
A. Comparing performance of the composite model to the performance of each single marker in the Moscow discovery sample. Combining the high specificity of CRP and IFNG+PTGS predictors (the left hump) with relatively high sensitivity of TGFB1 and FGB (the right hump) yields a much better classifier. B. Performance of the model stays the same when tested on the independent replication sample (Bashkortostan).
Fig 2The map of possible interactions between components of MI-associated biallelic combination IFNG and PTGS1 (black circles) and ten relative partners (gray circles) generated by GeneMania online software [45].
Possible physical interactions (pink), co-expression (violet), pathway (blue), genetic interactions (green), and shared protein domains (yellow) are shown. IDO1 –indoleamine 2,3–dioxygenase 1; IFNG–interferon gamma; IFNGR1 –interferon gamma receptor 1; IFNGR2 –interferon gamma receptor 2; IRF1 –interferon regulatory factor 1; MPO–myeloperoxidase; PTGIS–prostaglandin I2 (prostacyclin) synthase; PRKCD–protein kinase C delta; PTGS1 –prostaglandin–endoperoxide synthase 1; PTGS2 –prostaglandin–endoperoxide synthase 2; PTPN2 –protein tyrosine phosphatase, non–receptor type 2; PTPN6 –protein tyrosine phosphatase, non–receptor type 6.